Xie Bing and Zheng Xiangling, the major shareholders of China biopharmaceutical, give 21.45% equity to their son Xie Chengrun

On October 22, China biopharma released a notice on equity transfer of the company Mr Xie Bing and Ms Zheng Xiangling (executive director and main shareholder of the company) respectively transferred 450 million shares and 2.25 billion shares of China biopharma to their son Mr Xie Chengrun free of charge by way of gift After the transfer, Xie Chengrun held 2.7 billion shares of the company, with a shareholding ratio of 21 45% According to the announcement, validated profiles limited, a company wholly owned and controlled by Xie Bing, transferred 450 million shares of the company (accounting for about 3.57% of the total issued share capital of the company) to thousand Eagles limited, a company wholly owned and controlled by Xie Chengrun, free of charge by gift on Tuesday On the same day, Zhengda Centennial Group Co., Ltd., a company wholly owned and controlled by Zheng Xiangling, transferred 1.125 billion shares of the company (accounting for about 8.94% of the total issued share capital of the company) to thousandeagles limited free of charge by way of gift In addition, Zheng Xiangling transferred all the equity of his wholly-owned and controlled company, remarkable Industries Limited, to Xie Chengrun free of charge by way of gift At present, remarkable Industries Limited holds 1.125 billion shares of the company (accounting for about 8.94% of the total issued share capital of the company) Mr Xie Chengrun said that when passively participating in the rich list or wealth ranking compiled by the media or other units, he would try to avoid participating in the ranking in his own name, and would suggest participating in the name of the Xie Bing family (including Xie Bing, Zheng Xiangling, Xie qirun and Xie Chengrun) According to the announcement, the company has also been informed that the main shareholders' transfer of these shares is to improve the management and inheritance of family wealth; Xie Chengrun will hold the relevant shares for a long time; Xie Binghui will remain as the director and chairman of the company; all members of the Xie Bing family will continue to work with one heart and do their best to continuously improve the company's core competitiveness and realize the sustainable development of the company Therefore, the board of directors of the company believes that such share transfer will not have any significant impact on the business operation of the company.